When the first GLP-1 RA, exenatide, was released in 2005, the sole indication was for glycemic control, and weight loss was deemed a favorable side effect
Cardiovascular Safety: In 2008, the U.S
Pharmaceutical companies are researching the formulation of different transdermal patches for weight loss and diabetes, using efficient delivery technologies
Works throughout the entire body to promote cell migration, improve flexibility, and encourage new blood vessel formation, supporting recovery at a deeper, systemic level
Important: Prescription products require consultation with a state-licensed provider through our partner Orbit Health
We explore how changing oestrogen levels can make headaches and migraines worse, what these hormone headaches can feel like, plus the treatments that could help